Current status and future prospects of medical management for pancreatic neuroendocrine neoplasms

DOI Web Site 16 References
  • ITO Tetsuhide
    Neuroendocrine Tumor Centre, Fukuoka Sanno Hospital Department of Gastroenterology, Graduate School of Medical Sciences, Internal University of Health and Welfare
  • TAKAMATSU Yu
    Neuroendocrine Tumor Centre, Fukuoka Sanno Hospital
  • UEDA Keijiro
    Neuroendocrine Tumor Centre, Fukuoka Sanno Hospital Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences

Bibliographic Information

Other Title
  • 膵神経内分泌腫瘍（NEN）診療の現状および今後の展望

Search this article

Description

<p>In 2015, the Japanese Society for Neuroendocrine Tumors (JNETS) published the first clinical practice guidelines for pancreatic and gastrointestinal neuroendocrine neoplasms (NEN) to standardize diagnosis and treatment. NEN is a rare tumor that develops in all organs and presents with various clinical symptoms. Pathological classification is ultimately important for the diagnosis of NEN, and it is necessary to select drug treatment strategies based on the pathological diagnosis. The second edition of revised guidelines was published in 2019 to reflect new trends, including WHO classification revision, the advent of somatostatin receptor scintigraphy, the addition of target diseases for molecularly targeted drugs and the somatostatin analogue lanreotide, and reexamination of surgical indications for non-functional pancreatic NEN. Peptide receptor radionuclide therapy (PRRT) has also emerged. In this article, we review the current status and future prospects of pancreatic NEN management.</p>

Journal

  • Suizo

    Suizo 38 (6), 361-366, 2023-12-28

    Japan Pancreas Society

References(16)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top